<DOC>
	<DOCNO>NCT01060462</DOCNO>
	<brief_summary>The purpose observational study examine rate elevate body temperature ( fever ) relieve itraconazole injection administrate patient experience neutropenic fever . A neutropenic fever elevate body temperature occur time patient 's white blood cell count low . White blood cell aid body 's normal defense infection , fever period might make difficult patient fight infection .</brief_summary>
	<brief_title>Observational Study Investigating Response Rate Itraconazole Injection Treating Immunocompromised Patients</brief_title>
	<detailed_description>This study multi-center , open-label , prospective observational study enrol approximately 440 patient . The primary objective study examine fever response rate itraconazole IV ( directly vein ) administer 3 day patient neutropenic fever base investigator 's discretion . Follow-up perform administration 7 day administration . Study population consist patient visit study center study period judge neutropenic fever associate hematologic malignancy acute leukemia , hodgkin 's lymphoma , non-hodgkin 's lymphoma , myelodysplastic syndrome , multiple myeloma . The decision treat patient itraconazole per physician discretion dos determine base upon approved labeling recommendation physician discretion . The safety efficacy itraconazole administer beyond 29 day yet establish treatment fever neutropenic patient suspect systemic fungal infection . Itraconazole 200 mg IV twice daily 2 day , total 4 dos , 200 mg IV daily 12 day . After administration total 14 day , itraconazole oral solution 200 mg ( 20 ml ) twice daily continue total 14 day</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Patients neutropenic fever receive antineoplastic therapy stem cell transplantation acute leukemia , hodgkin 's lymphoma , nonhodgkin 's lymphoma , myelodysplastic syndrome , multiple myeloma Patients recommend receive itraconazole injection treatment acute leukemia , hodgkin 's lymphoma , nonhodgkin 's lymphoma , myelodysplastic syndrome , multiple myeloma Childbearing woman pregnant likely pregnant study period male patient neither infertile willing refrain sexual relation whose partner conduct effective contraception ( implant , injection , oral contraceptive , intrauterine device , etc . ) Fever due document deepseated fungal infection entry study ( document candidemia include ) Significant hepatic renal dysfunction Patients , discretion investigator , eligible study participation base warning , precaution contraindicate medication list package insert drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Defervescence rate</keyword>
	<keyword>Defervescence timing</keyword>
	<keyword>Itraconazole</keyword>
</DOC>